Investor FAQ

What exchange does DRI Healthcare Trust trade on and what is its ticker symbol?

DRI Healthcare Trust’s units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol “DHT.UN” and in U.S. dollars under the symbol “DHT.U”.

What is DRI Healthcare Trust’s fiscal year-end?

Our fiscal year-end is December 31.

Who is the transfer agent for publicly traded units of DRI Healthcare Trust?

Our transfer agent is Computershare Investor Services Inc. They can be reached by phone at (416) 263-9200 or online at www.computershare.com/ca/en/contact-us.

Who should I contact if I lost or misplaced my unit certificates; if I have changed my address; or have estate, trust or corporate transfers?

Please contact our transfer agent of record — Computershare Investor Services Inc. They can be reached by phone at (416) 263-9200 or online at www.computershare.com/ca/en/contact-us.

Who is the auditor for DRI Healthcare Trust?

Our auditor is Deloitte LLP, Chartered Professional Accountants, based in Toronto, Ontario.

When are the distribution dates of record?

The record dates for units of DRI Healthcare Trust are on the last day of March, June, September and December.

In which currency are the distribution paid?

The quarterly distribution payable on units of DRI Healthcare Trust is declared in U.S. dollars.

Where can I find current information on DRI Healthcare Trust’s unit price?

You can find our unit price information on our website at www.dricapital.com/investors/stock-information/ and on the TMX Group website at www.tmx.com.

Where can I find information on insider ownership positions for DRI Healthcare Trust?

Insider ownership information is available on the System for Electronic Disclosure by Insiders (“SEDI”) at www.sedi.ca.

Questions about pharmaceutical royalties

What is a traditional pharmaceutical royalty?

A typical licensing transaction involves granting rights to use intellectual property or know how created by an inventor, academic institution or drug developer to develop and commercialize a product in exchange for upfront cash payments, royalties or other economic consideration. The amount of royalties payable under such a license agreement is typically a percentage of the net sales of the relevant product. Traditional royalty investing involves a purchaser paying an initial purchase price to the licensor of intellectual property or know how in return for the purchaser being entitled to receive some or all of the royalties to which the licensor is entitled under the license agreement.

What is a synthetic royalty?

Synthetic royalty transactions involve the creation of a new royalty stream, whereby the buyer contracts directly with the marketer to receive a portion of top-line product sales in exchange for funding. As biotechnology companies continue to conduct their own research and development to bring their own internally developed technologies to market, synthetic royalties have become an increasingly important tool for these companies to finance ongoing capital requirements through non-dilutive means.

How is investing in pharmaceutical royalties potentially less risky than directly investing in pharmaceutical companies?

Pharmaceutical royalties represent direct investments in pharmaceutical sales with less exposure to many of the traditional risks associated with the pharmaceutical industry, including clinical development, a focus on core therapeutic areas due to R&D and salesforce limitations, product commercialization risks (including limitations on product and geographical diversity and being subject to intense regulatory processes and development timelines), expenses relating to R&D, manufacturing, sales and marketing and potential liability risks.

Are the expected returns from pharmaceutical royalty funds highly correlated to traditional asset class returns?

Historically, the pharmaceutical royalty market has been observed as having a low correlation to credit or equity markets. Instead, returns have been more closely linked to broader trends in demographics such as overall population growth and the ageing of the population, as well as general acceleration in medical research, which has advanced treatments across a range of therapeutic areas from oncology to rare diseases. It’s also important to point out that our disciplined investment strategy is predicated on active sourcing of royalties on medically necessary products with long term patent lives. Medically necessary products are generally demand inelastic, meaning that they are less sensitive to price changes than other products.